

# MOLECULAR PHARMACOLOGY

EDITOR: RAYMOND J. DINGLELINE, *Emory University*

ASSOCIATE EDITORS: P. JEFFREY CONN, *Emory University*  
MICHAEL M. GOTTESMAN, *National Institutes of Health*  
BRIAN K. KOBILKA, *Stanford University*  
KENNETH P. MINNEMAN, *Emory University*  
EDWARD T. MORGAN, *Emory University*

MANAGING EDITOR: WENDY M. WILEY

EDITORIAL ASSISTANT: ESMERALDA GALÁN

## EDITORIAL AND ADVISORY BOARD

NIGEL J. M. BIRDSALL, *National Institute for Medical Research, Mill Hill, United Kingdom*

RANDY D. BLAKELEY, *Vanderbilt University*

JOËL BOCKAERT, *Centre National de la Recherche Scientifique, France*

EDWARD BRESNICK, *University of Massachusetts Medical Center*

JOAN HELLER BROWN, *University of California, San Diego*

MARC G. CARON, *Duke University*

CHARLES CHAVKIN, *University of Washington*

JOHN W. DALY, *National Institutes of Health*

STEVEN K. FISHER, *University of Michigan*

ALFRED G. GILMAN, *University of Texas Southwestern Medical Center, Dallas*

ROBERT I. GLAZER, *Georgetown University*

FRANK J. GONZALEZ, *National Cancer Institute*

F. PETER GUENGERICH, *Vanderbilt University*

JAMES R. HALPERT, *University of Arizona*

HEIDI HAMM, *University of Illinois College of Medicine*

R. ADRON HARRIS, *University of Colorado Health Sciences Center, Denver*

STEPHEN B. HOWELL, *University of California, San Diego*

PAUL A. INSEL, *University of California, San Diego*

KARL H. JAKOBS, *University of Essen, Germany*

ERIC F. JOHNSON, *The Scripps Research Institute*

DENNIS R. KOOP, *Oregon Health Sciences University*

ROBERT J. LEFKOWITZ, *Duke University*

LEE E. LIMBIRD, *Vanderbilt University*

THOMAS M. LINCOLN, *University of Alabama at Birmingham*

JOEL LINDEN, *University of Virginia*

ROBERT L. MACDONALD, *University of Michigan Medical Center*

RONALD P. MASON, *National Institute of Environmental Health Sciences*

MARK L. MAYER, *National Institutes of Health*

JAMES O. MCNAMARA, *Duke University*

RICHARD J. MILLER, *University of Chicago*

GRAEME MILLIGAN, *University of Glasgow, Scotland*

T. J. MURPHY, *Emory University*

CHARLES E. MYERS, JR., *University of Virginia Health Sciences Center*

S. R. NAHORSKI, *University of Leicester, United Kingdom*

DAVID L. NELSON, *Lilly Research Laboratories*

ERIC J. NESTLER, *Yale University*

RICHARD R. NEUBIG, *University of Michigan*

KIM A. NEVE, *Veterans Affairs Medical Center, Portland*

ALLAN B. OKEY, *University of Toronto, Canada*

PAUL ORTIZ DE MONTELLANO, *University of California, San Francisco*

GERRY S. OXFORD, *University of North Carolina at Chapel Hill*

ERIC M. PARKER, *Bristol-Myers Squibb Company*

ALAN POLAND, *University of Wisconsin*

MICHAEL A. ROGAWSKI, *National Institutes of Health*

DARRYLE D. SCHOEPP, *Eli Lilly and Company*

GARY L. STILES, *Duke University*

CATHERINE D. STRADER, *Merck Research Laboratories*

PALMER TAYLOR, *University of California, San Diego*

TODD A. VERDOORN, *Vanderbilt University*

MICHAEL J. WARING, *University of Cambridge, England*

DAVID J. WAXMAN, *Boston University*

GARY L. WESTBROOK, *Vollum Institute*

MICHAEL M. WHITE, *Medical College of Pennsylvania*

STEVEN A. WRIGHTON, *Lilly Research Laboratories*

## BOARD OF PUBLICATIONS TRUSTEES

KENNETH E. MOORE, *Chairman*

KAY A. CROKER, *Executive Officer*

WILLIAM O. BERNDT

D. CRAIG BRATER

DAVID B. BYLUND

WILLIAM A. CATTERALL

MARLENE L. COHEN

RAYMOND J. DINGLELINE

JOHN A. HARVEY

RAYMOND F. NOVAK

MARCUS M. REIDENBERG

*About the cover:* Depiction of a model of the cholecystokinin B receptor, showing longitudinal views of the seven transmembrane helices (blue), the intracellular domains i1 (yellow), i2 (red), and i3 (green), and the carboxyl-terminal tail (deep yellow). Mutational deletion of the carboxyl group from the Asp<sup>100</sup> residue in the TMII region (yellow) substantially weakened the ability of this receptor to couple to its G protein. From Jagerschmidt A., N. Guillaume, N. Goudreau, B. Maigret, and B.-P. Roques. Mutation of Asp<sup>100</sup> in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. *Mol. Pharmacol.* 48:783–789 (1995).